Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome
The purpose of this study is to evaluate the efficacy, safety, tolerability, and
pharmacokinetics (PK) of teduglutide compared with placebo in subjects with parenteral
nutrition (PN)-dependent short bowel syndrome (SBS).
Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects
Teduglutide is an investigative medicine being evaluated as a possible treatment for people
with parenteral nutrition (PN) dependent Short Bowel Syndrome (SBS). Teduglutide is similar
to a protein the body makes. When people have SBS, their bodies do not make enough of the
protein and they have trouble getting nutrients and fluids from the food they eat and drink.
This study was designed to provide evidence of efficacy, safety, and tolerability of
teduglutide 0.05 mg/kg daily in SBS subjects.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.